Skip to content
  • Fact Sheet
  • Contact
  • Blog
  • English English
    • English English
    • Español Español
OligofastxOligofastx
  • ABOUT OLIGOFASTX
    • ABOUT OLIGOFASTX
      • About the project
      • Mission, Vision and Goals
      • Oligonucleotides
  • Rare diseases
    • Retinitis Pigmentosa
    • Leber Congenital Amaurosis
    • Cancer cachexia
    • Alström Syndrome
    • Fuchs’ corneal endothelial dystrophy
    • Guillain-Barré syndrome
    • Anaplastic thyroid cancer
  • TECHNOLOGIES
    • Design, Artificial Intelligence and Modelling
      • Artificial Intelligence
    • THERAPY DEVELOPMENT
      • sIRNA
      • Aptamer
      • Anti-miRNA
    • NANOTECHNOLOGY AND DRUG DELIVERY
      • Drug nanoliberation
      • Bioconjugates
    • PRODUCTION AND SCALING UP
      • Oligonucleotide scale-up and biosynthesis
  • Partner companies
    • Sylentis
    • aptaTargets
    • AptusBiotech
    • Arthex
    • Nanovex
    • Nostrum Biodiscovery
    • 53Biologics
  • Collaborators
  • Strategy

oligofastx-blog-resumen2022-14

https://oligofastx.com/wp-content/uploads/2022/12/oligofastx-blog-resumen2022-14.mp4
This entry was posted in . Bookmark the permalink.
Goodbye 2022, welcome 2023
Latest Posts
  • 30
    Mar
    Artificial Intelligence applied to the diagnosis and treatment of rare diseases Comments Off on Artificial Intelligence applied to the diagnosis and treatment of rare diseases
  • 22
    Mar
    Tribute to Severo Ochoa, the Spanish biochemist who received the Nobel Prize for discovering the enzymes involved in RNA synthesis. Comments Off on Tribute to Severo Ochoa, the Spanish biochemist who received the Nobel Prize for discovering the enzymes involved in RNA synthesis.
  • 14
    Mar
    Spanish pharmaceutical industry, third largest exporter with 53% growth to 2022 Comments Off on Spanish pharmaceutical industry, third largest exporter with 53% growth to 2022
  • 08
    Mar
    #8M, #InternationalWomensDay: “For an inclusive digital world” Comments Off on #8M, #InternationalWomensDay: “For an inclusive digital world”
  • 28
    Feb
    Rare Disease Day Comments Off on Rare Disease Day
Categories
  • Noticias (14)
  • Rare diseases (5)
  • Technology (2)
  • Uncategorized (10)
Archives
  • March 2023 (4)
  • February 2023 (4)
  • January 2023 (4)
  • December 2022 (4)
  • November 2022 (3)
  • October 2022 (3)
  • September 2022 (2)
  • July 2022 (1)

About OLIGOFASTX

Comprehensive platform for the sustainable development of oligonucleotide-based therapies.

OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) with the participation of six other Spanish companies: Nanovex Biotechnologies (Grupo Industrial Química del Nalón), Aptus Biotech, AptaTargets, Arthex Biotech, Nostrum Biodiscovery and 53Biologics.

Subsidised by the CDTI

Shortcuts

What is OLIGOFASTX
Rare diseases
Design, Modelling and Artificial Intelligence
Therapy development
Nanotechnology and drug delivery
Production and scaling
Partners
Collaborators
Strategy

partners

  • Fact Sheet
  • Legal Advice
  • Privacy Policy
  • Cookie Policy
  • Contact
Copyright 2023 © OLIGOFASTX
  • ABOUT OLIGOFASTX
    • ABOUT OLIGOFASTX
      • About the project
      • Mission, Vision and Goals
      • Oligonucleotides
  • Rare diseases
    • Retinitis Pigmentosa
    • Leber Congenital Amaurosis
    • Cancer cachexia
    • Alström Syndrome
    • Fuchs’ corneal endothelial dystrophy
    • Guillain-Barré syndrome
    • Anaplastic thyroid cancer
  • TECHNOLOGIES
    • Design, Artificial Intelligence and Modelling
      • Artificial Intelligence
    • THERAPY DEVELOPMENT
      • sIRNA
      • Aptamer
      • Anti-miRNA
    • NANOTECHNOLOGY AND DRUG DELIVERY
      • Drug nanoliberation
      • Bioconjugates
    • PRODUCTION AND SCALING UP
      • Oligonucleotide scale-up and biosynthesis
  • Partner companies
    • Sylentis
    • aptaTargets
    • AptusBiotech
    • Arthex
    • Nanovex
    • Nostrum Biodiscovery
    • 53Biologics
  • Collaborators
  • Strategy
  • English English
    • English English
    • Español Español
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}
  • English
  • Español